Pioneer Investment Management Inc. raised its position in Astrazeneca PLC (NYSE:AZN) by 1.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,199,570 shares of the company’s stock after buying an additional 13,767 shares during the period. Pioneer Investment Management Inc.’s holdings in Astrazeneca PLC were worth $40,894,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. TD Asset Management Inc. raised its stake in shares of Astrazeneca PLC by 0.6% in the second quarter. TD Asset Management Inc. now owns 905,684 shares of the company’s stock worth $30,875,000 after buying an additional 5,421 shares during the last quarter. First Bank & Trust raised its position in Astrazeneca PLC by 31.4% in the second quarter. First Bank & Trust now owns 43,399 shares of the company’s stock valued at $1,479,000 after buying an additional 10,378 shares in the last quarter. IFP Advisors Inc raised its position in Astrazeneca PLC by 28.5% in the second quarter. IFP Advisors Inc now owns 14,570 shares of the company’s stock valued at $497,000 after buying an additional 3,235 shares in the last quarter. Sei Investments Co. raised its position in Astrazeneca PLC by 7.9% in the second quarter. Sei Investments Co. now owns 1,063,642 shares of the company’s stock valued at $36,259,000 after buying an additional 78,297 shares in the last quarter. Finally, Suffolk Capital Management LLC purchased a new position in Astrazeneca PLC during the second quarter valued at $12,591,000. 14.30% of the stock is currently owned by hedge funds and other institutional investors.
Astrazeneca PLC (NYSE AZN) traded up 0.14% during midday trading on Friday, reaching $29.12. The company’s stock had a trading volume of 4,185,092 shares. The stock has a 50 day moving average of $31.67 and a 200 day moving average of $31.48. Astrazeneca PLC has a 52 week low of $25.55 and a 52 week high of $35.60. The firm has a market capitalization of $73.73 billion, a PE ratio of 19.10 and a beta of 0.74.
The company also recently declared a None dividend, which will be paid on Monday, September 11th. Shareholders of record on Friday, August 11th will be issued a $0.44 dividend. The ex-dividend date is Wednesday, August 9th. This represents a yield of 2.98%. Astrazeneca PLC’s dividend payout ratio (DPR) is 44.92%.
WARNING: “Astrazeneca PLC (AZN) Position Boosted by Pioneer Investment Management Inc.” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/08/19/pioneer-investment-management-inc-has-40-89-million-stake-in-astrazeneca-plc-azn-updated.html.
Several equities analysts have recently weighed in on the company. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, August 9th. BidaskClub lowered Astrazeneca PLC from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Cowen and Company reaffirmed a “hold” rating and issued a $34.00 price objective on shares of Astrazeneca PLC in a research note on Friday, July 28th. Morgan Stanley lowered Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, July 28th. Finally, Barclays PLC reaffirmed an “overweight” rating on shares of Astrazeneca PLC in a research note on Thursday, July 13th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have issued a buy rating to the stock. Astrazeneca PLC has an average rating of “Hold” and an average target price of $33.39.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
What are top analysts saying about Astrazeneca PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Astrazeneca PLC and related companies.